PriceTargets.com logo

NASDAQ:PTGX - Protagonist Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.63
  • Forecasted Upside: 557.47 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$7.70 As of 05/24/2022 01:00 AM ET
▼ -0.13 (-1.66%)

This chart shows the closing price for PTGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Protagonist Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTGX

Analyst Price Target is $50.63
▲ +557.47% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is $50.63, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 557.47% upside from the last price of $7.70.

This chart shows the closing price for PTGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Protagonist Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2022Piper SandlerLower Price TargetOverweight$60.00 ➝ $35.00High
4/26/2022BTIG ResearchLower Price Target$55.00 ➝ $45.00High
4/14/2022BTIG ResearchReiterated RatingBuy$55.00N/A
2/11/2022BTIG ResearchInitiated CoverageBuy$55.00Low
11/15/2021JMP SecuritiesBoost Price TargetPositive ➝ Outperform$60.00 ➝ $70.00High
10/13/2021JMP SecuritiesBoost Price TargetHold ➝ Outperform$47.00 ➝ $60.00Low
10/12/2021SVB LeerinkBoost Price TargetOutperform$35.00 ➝ $50.00High
10/12/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$49.00 ➝ $55.00High
10/11/2021Jefferies Financial GroupBoost Price TargetHold ➝ Buy$29.00 ➝ $60.00High
10/11/2021Northland SecuritiesUpgradeMarket Perform ➝ Outperform$40.00High
9/22/2021JMP SecuritiesLower Price TargetMarket Outperform$55.00 ➝ $47.00Low
9/20/2021HC WainwrightReiterated RatingBuy$60.00 ➝ $50.00High
9/20/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$60.00 ➝ $49.00High
9/17/2021JMP SecuritiesReiterated RatingHold ➝ Buy$47.00 ➝ $55.00High
8/6/2021HC WainwrightBoost Price TargetBuy$50.00 ➝ $60.00Low
8/5/2021SVB LeerinkBoost Price TargetOutperform$41.00 ➝ $50.00Medium
7/30/2021Piper SandlerBoost Price TargetOverweight$53.00 ➝ $93.00High
6/18/2021HC WainwrightBoost Price TargetBuy$36.00 ➝ $50.00Medium
6/14/2021Northland SecuritiesBoost Price TargetOutperform$42.00 ➝ $47.00Medium
5/24/2021JMP SecuritiesInitiated CoverageMarket Outperform$48.00High
5/24/2021Northland SecuritiesInitiated CoverageOutperform$42.00High
3/11/2021HC WainwrightBoost Price TargetBuy$33.00 ➝ $36.00High
3/3/2021SVB LeerinkBoost Price TargetPositive ➝ Outperform$30.00 ➝ $41.00High
1/6/2021JPMorgan Chase & Co.Initiated CoverageOverweight$35.00N/A
12/16/2020Piper SandlerInitiated CoverageOverweight$53.00N/A
12/7/2020BMO Capital MarketsBoost Price Target$37.00 ➝ $46.00High
9/18/2020HC WainwrightBoost Price TargetBuy$28.00 ➝ $33.00High
7/15/2020Jefferies Financial GroupInitiated CoverageBuy$27.00High
5/22/2020SVB LeerinkBoost Price TargetOutperform$17.00 ➝ $30.00High
5/13/2020HC WainwrightReiterated RatingBuy$23.00 ➝ $28.00Low
5/11/2020NomuraBoost Price TargetBuy$29.00 ➝ $33.00Medium
5/11/2020Nomura InstinetBoost Price TargetBuy$29.00 ➝ $33.00Medium
8/13/2019SVB LeerinkReiterated RatingOutperformMedium
8/11/2019Nomura SecuritiesReiterated RatingBuy$29.00Low
8/2/2019HC WainwrightSet Price TargetBuy$23.00Low
7/8/2019HC WainwrightInitiated CoverageBuy ➝ Buy$23.00High
5/8/2019Stifel NicolausUpgradeHold ➝ Buy$11.00 ➝ $17.00High
2/22/2019BMO Capital MarketsInitiated CoverageOutperform$17.00Medium
12/6/2018Nomura SecuritiesInitiated CoverageBuy ➝ Buy$13.00Low
8/6/2018SVB LeerinkBoost Price TargetOutperform$13.00 ➝ $21.00High
6/6/2018BarclaysDowngradeOverweight ➝ Equal Weight$18.00Low
3/26/2018BMO Capital MarketsReiterated RatingBuy ➝ Outperform$42.00 ➝ $13.00Low
3/26/2018Stifel NicolausDowngradeBuy ➝ HoldMedium
3/8/2018BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$44.00 ➝ $42.00Low
1/29/2018Stifel NicolausInitiated CoverageBuy ➝ Buy$32.00High
11/7/2017BMO Capital MarketsBoost Price TargetOutperform$40.00 ➝ $43.00N/A
10/19/2017BMO Capital MarketsLower Price TargetOutperform$45.00 ➝ $40.00N/A
7/21/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$36.00Medium
5/31/2017BMO Capital MarketsBoost Price TargetOutperform$34.00 ➝ $45.00High
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/27/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/26/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
4/25/2022
  • 4 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2022

Current Sentiment

  • 4 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Protagonist Therapeutics logo
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Read More

Today's Range

Now: $7.70
Low: $7.39
High: $7.78

50 Day Range

MA: $17.37
Low: $7.70
High: $27.26

52 Week Range

Now: $7.70
Low: $7.39
High: $50.54

Volume

921,494 shs

Average Volume

1,023,654 shs

Market Capitalization

$374.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Protagonist Therapeutics?

The following equities research analysts have issued research reports on Protagonist Therapeutics in the last year: BTIG Research, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Northland Securities, Piper Sandler, StockNews.com, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for PTGX.

What is the current price target for Protagonist Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Protagonist Therapeutics in the last year. Their average twelve-month price target is $50.63, suggesting a possible upside of 557.5%.
View the latest price targets for PTGX.

What is the current consensus analyst rating for Protagonist Therapeutics?

Protagonist Therapeutics currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTGX will outperform the market and that investors should add to their positions of Protagonist Therapeutics.
View the latest ratings for PTGX.

How do I contact Protagonist Therapeutics' investor relations team?

Protagonist Therapeutics' physical mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company's listed phone number is (510) 474-0170 and its investor relations email address is [email protected] The official website for Protagonist Therapeutics is www.protagonist-inc.com. Learn More about contacing Protagonist Therapeutics investor relations.